<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583684</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-46131</org_study_id>
    <nct_id>NCT03583684</nct_id>
  </id_info>
  <brief_title>Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism</brief_title>
  <acronym>PRT-I</acronym>
  <official_title>Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autism spectrum disorder (ASD) is a very heterogeneous disorder with limited empirically&#xD;
      validated behavioral and biological interventions. The goal of this pilot investigation is to&#xD;
      apply a biologically-based approach to identify predictors of treatment response in children&#xD;
      with ASD who are receiving Pivotal Response Treatment (PRT), an evidence-based behavioral&#xD;
      intervention. Specifically, the investigators propose to identify neuroimaging biomarkers of&#xD;
      treatment response to a PRT program (PRT-P) targeting language deficits in young children&#xD;
      with ASD who will be randomized to either PRT-P or to a delayed treatment group (DTG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of Child Utterances During a Structured Lab Observation (SLO)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on MacArthur-Bates Communication Development Inventory (CDI)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change on Preschool Language Scale, 5th Edition (PLS-5)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on Mullen Scales of Early Learning</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on Vineland Adaptive Behaviors Scales, 3rd Edition</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on Clinical Global Impressions Scale (CGI)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on the Brief Observation of Social Communication Change (BOSCC) direct child observation assessment</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on Parent Stress Index (PSI)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on Family Empowerment Scale (FES)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change on General Self Efficacy Scale (GSES)</measure>
    <time_frame>Baseline, 16 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Pivotal Response Treatment Program (PRT-P)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Treatment Group (DTG)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Child continues stable treatments as usual in the community.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pivotal Response Treatment Program (PRT-P)</intervention_name>
    <description>The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.</description>
    <arm_group_label>Pivotal Response Treatment Program (PRT-P)</arm_group_label>
    <other_name>Pivotal Response Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Autism Spectrum Spectrum Disorder (ASD) based on clinical interview and&#xD;
             Diagnostic and Statistical Manual, 5th edition (DSM-5) and confirmed using the Autism&#xD;
             Diagnostic Interview Revised (ADI-R) and the Autism Diagnostic Observation Schedule&#xD;
             (ADOS) and/or Brief Observation of Symptoms of Autism (BOSA) and/or Childhood Autism&#xD;
             Rating Scale- Second Edition (CARS-2).&#xD;
&#xD;
          -  Outpatients between 2.0 and 4.11 years of age of either gender,&#xD;
&#xD;
          -  Children of all cognitive levels will be included as long as they are able to&#xD;
             participate in the testing procedures to the extent that valid standard scores can be&#xD;
             obtained&#xD;
&#xD;
          -  Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5) [at&#xD;
             least 1 standard deviation behind for children age 2 and 3 years; and 2 standard&#xD;
             deviations behind for children age 4],&#xD;
&#xD;
          -  Stable psychotropic medication(s) or biomedical intervention(s) for at least 1 month&#xD;
             prior to baseline measurements with no anticipated changes during study participation,&#xD;
&#xD;
          -  Stable treatment [Applied Behavior Analysis (ABA), Floortime, or other interventions],&#xD;
             speech therapy, and school placement for at least 1 month prior to baseline&#xD;
             measurements with no expected changes during study participation,&#xD;
&#xD;
          -  No more than 60 minutes of 1:1 speech therapy per week,&#xD;
&#xD;
          -  The child's exposure to the English language must be sufficient that administration of&#xD;
             standardized tests in English is appropriate for measuring progress,&#xD;
&#xD;
          -  The availability of at least one parent who can consistently participate in the&#xD;
             training sessions and related activities, and&#xD;
&#xD;
          -  Successful completion of baseline brain scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or life-time diagnosis of severe psychiatric disorder (e.g., bipolar&#xD;
             disorder),&#xD;
&#xD;
          -  Genetic abnormality (e.g., Fragile X)&#xD;
&#xD;
          -  Presence of active medical problem (e.g., unstable seizure disorder),&#xD;
&#xD;
          -  Receiving more than 15 hours of in home 1:1 Applied Behavior Analysis (ABA) per week&#xD;
&#xD;
          -  Magnetic Resonance (MR) contraindication (e.g., the presence of ferrous metal), or&#xD;
&#xD;
          -  Previous adequate Pivotal Response Treatment (PRT) trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Hardan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Estefania Millan, MA</last_name>
    <phone>(650) 736-1235</phone>
    <email>mmillan2@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Hegarty, PhD</last_name>
    <phone>(650) 736-1235</phone>
    <email>hegartyj@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estefania Millan, MA</last_name>
      <phone>650-736-1235</phone>
      <email>mmillan2@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Libove, BS</last_name>
      <phone>(650) 736-1235</phone>
      <email>rlibove@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Y. Hardan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Antonio Hardan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pivotal Response Treatment</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

